Roberta Scafetta

Via Alvaro Del Portillo 200
Rome, 00128, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.

Journal: European journal of cancer (Oxford, England : 1990)
Published: July 14, 2026

Artificial intelligence for bone metastases: a systematic review and meta-analysis of diagnostic and prognostic performance.

Artificial intelligence for bone metastases: a systematic review and meta-analysis of diagnostic and prognostic performance.

Journal: Frontiers in oncology
Published: June 22, 2026

Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.

Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.

Journal: European journal of cancer (Oxford, England : 1990)
Published: December 23, 2025

Prognostic significance of circulating tumor DNA in early breast cancer: a systematic review and meta-analysis.

Prognostic significance of circulating tumor DNA in early breast cancer: a systematic review and meta-analysis.

Journal: Breast cancer research and treatment
Published: November 07, 2025

Immunotherapy in rare histologies of breast cancer: challenges, opportunities, and future perspectives.

Immunotherapy in rare histologies of breast cancer: challenges, opportunities, and future perspectives.

Journal: Current opinion in oncology
Published: August 21, 2025

Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2- breast cancer patients with bone metastases.

Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2- breast cancer patients with bone metastases.

Journal: The oncologist
Published: June 13, 2025

Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer.

Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer.

Journal: JAMA network open
Published: February 21, 2025

ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy.

ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy.

Journal: Breast cancer research : BCR
Published: January 19, 2025

Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer.

Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer.

Journal: Breast (Edinburgh, Scotland)
Published: November 19, 2024

Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors.

Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors.

Journal: Breast (Edinburgh, Scotland)
Published: October 22, 2024

The Safety and Suitability of DNA Sequencing of Tissue Biopsies Performed on Patients Referred to a Phase I Unit.

The Safety and Suitability of DNA Sequencing of Tissue Biopsies Performed on Patients Referred to a Phase I Unit.

Journal: Cancers
Published: October 10, 2024

Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment.

Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment.

Journal: NPJ breast cancer
Published: October 08, 2024
Showing 1-12 of 18

Last Updated: 09/26/2026